Advertisement

Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer

  • A. U. Buzdar
  • T. L. Smith
  • C. E. Marcus
  • G. N. Hortobagyi
  • G. R. Blumenschein
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 96)

Abstract

In the past decade, many adjuvant chemotherapy trials in operable breast cancer have been conducted. The results of these trials have answered a number of questions, but have also raised new issues. Among other issues, results have suggested that relapse-free survival was dependent on the dose of cytotoxic drugs and the timing of initiation of chemotherapy [1, 2]. Routine postoperative irradiation was shown to have a detrimental effect on the efficacy of adjuvant chemotherapy [2, 3]. At M.D. Anderson Hospital, since 1974, a combination of fluorouracil, doxorubicin (adriamycin), and cyclophosphamide (FAC) has been utilized following regional therapy in patients with operable breast cancer. In this paper the dose of cytotoxic drugs, timing of initiation of chemotherapy, and the role of routine postoperative irradiation are evaluated.

Keywords

Breast Cancer Adjuvant Chemotherapy Operable Breast Cancer Granulocyte Count Pretreatment Characteristic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cooper RG, Holland JF, Glidewell O (1979) Adjuvant chemotherapy of breast cancer. Cancer 44: 793–798PubMedCrossRefGoogle Scholar
  2. 2.
    Bonadonna G, Valagussa P (1981) Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15PubMedCrossRefGoogle Scholar
  3. 3.
    Nissen-Meyer R, Kjellgren K Malmio K et al. (1978) Surgical adjuvant chemotherapy results with one short course with cyclophosphamide alter mastectomy for breast cancer. Cancer 41: 2008–2098CrossRefGoogle Scholar
  4. 4.
    Buzdar A, Smith T, Blumenschein G, Hortobagyi G, Hersh E, Gehan E (1981) Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or III breast cancer: 5-year results. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton, New York, pp 419–426Google Scholar
  5. 5.
    Buzdar A. Blumenschein G, Smith T et al. (1984) Adjuvant chemotherapy with fluorouracil, doxorubicin, and cylophosphamide, with our without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer 53: 384–389Google Scholar
  6. 6.
    Buzdar A, Gutterman J, Blumenschein G et al. (1978) Intensive postoperative chemoimmunotherapy for patients with operable breast cancer. Cancer 41: 1064–1075PubMedCrossRefGoogle Scholar
  7. 7.
    Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–225PubMedGoogle Scholar
  8. 8.
    Breslow N (1970) A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 57: 579–594CrossRefGoogle Scholar
  9. 9.
    Buzdar A, Smith T, Powell K et al. (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Cancer Res Treat 2: 163–169CrossRefGoogle Scholar
  10. 10.
    Buzdar A, Smith T, Blumenschein G et al. (1984) Adjuvant therapy for stage II or III breast cancer M.D. Anderson Hospital experience. In: Blumenschein GR, Montague E (eds) Current controversy in breast cancer. Proceedings of the 26th annual clinical conference, New York, pp 171–184Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • A. U. Buzdar
    • 1
    • 2
  • T. L. Smith
    • 1
    • 2
  • C. E. Marcus
    • 1
    • 2
  • G. N. Hortobagyi
    • 1
    • 2
  • G. R. Blumenschein
    • 1
    • 2
  1. 1.M.D. Anderson Hospital and Tumor InstituteUniversity of Texas System Cancer CenterHoustonUSA
  2. 2.Department of Medical OncologyMedical Breast ServiceHoustonUSA

Personalised recommendations